Urological Surgeon.
Melbourne, Victoria
Joined March 2009
- Tweets798
- Following631
- Followers420
- Likes1.3K
Niranjan Sathianathen retweeted
Great to finally see the results of the #PROTEUS substudy comparing #perioperative Apa+ADT with the true SOC (RP w/o neoadjuvant treatment) - which should at least reduce some concerns related to the active comparator with ADT in the main study that didn’t reflect what we actually do as a standard in HR patients #ESMO26
Outcomes in all #endpoints significant improved
✅EFS: HR 0.38, 95% CI 0.26–0.55
✅MFS: HR 0.49, 95% CI 0.26–0.90
✅TT 1st Sub Rx: HR 0.29, 95% CI 0.20–0.43
The question remains which of these outcomes are most clinically relevant and meaningful #PROTEUS #ProstateCancer #UrologicOncology #Apalutamide #RadicalProstatectomy @oncodaily @OncoDailyGU @urotoday @Albert0Briganti @JNJInnovMed
Niranjan Sathianathen retweeted
🚨 New in @JUrology: "Language as a powerful influencer in #ProstateCancer" 🚨
✒️ New essay w/ @uroegg & Jessica Rett @LinguisticsUcla
📄 Words are neither neutral nor fixed
♋️We use prostate cancer, a disease spanning indolent to lethal under one name, as a case study:
👉 MRI "lesion"
👉 clinically "significant" disease
👉 "positive" margin
❓ We all know these terms shape how patients hear us
🧵 5 strategies you can use today 👇
Niranjan Sathianathen retweeted
An 8 year labor of love to get this study complete but it's finally here-- a comprehensive longitudinal assessment of >250,000 @VeteransHealth patients with de novo #microhematuria, details on their cystoscopy evals, and risk factors for MH-related bladder cancer diagnoses.
Niranjan Sathianathen retweeted
Cochrane on HoLEP: 52 RCTs, 6,242 men, no external funding, search to April 2026.
Vs TURP at 12 months: similar symptoms, QoL, major AEs, retreatment, erectile function. One clear win: transfusions, RR 0.19.
I do HoLEP. I accept this. Thread.
#MISTAudit #BPH #Urology
Niranjan Sathianathen retweeted
🚨 Half of focal therapy for #ProstateCancer in the US is happening where no guideline supports it 🚨
@JAMA_current research letter
👥 1,179,384 pts w/ nonmetastatic PCa, NCDB 2010 to 2023
📊 15,672 (1.3%) got focal therapy
⚠️ 51% was in low, high, or very high risk disease.
-No guideline supports routine use in ANY risk group outside trials or registries
⚠️ Low risk held flat (1.8% to 2.2%) and favorable intermediate is rising (2.1% to 2.9%) while marketing and&reimbursement expand
⚠️ Focal therapy more likely w/ age ≥75 (adjusted probability 22.9%), community centers (7.6% vs 2.5% academic), nonprivate insurance
✒️From the accompanying editorial
"Volume of this kind shows diffusion, not benefit."
🎯 Key points
1⃣In low risk this converts surveillance candidates into procedure pts
2⃣In high risk it is undertreatment.
3⃣Repeated use is building "an aura of legitimacy the data have not earned." We owe pts trials, not marketing.
🔗 Study: doi.org/10.1001/jama.2026.12…
🔗 Editorial: doi.org/10.1001/jama.2026.16…
@QDTrinh @DrSpratticus @AmerUrological @UroOnc @SUO_YUO @urotoday @UrologyTimes @PCF_Science @PCFnews
Niranjan Sathianathen retweeted
We have completed our first Robotic Retroperitoneal Lymph Node Dissection @Austin_Health. Patients potentially only need to stay overnight. Again we are thankful to have the Da Vinci Xi robotic system. Thank you Prof. Lawrentschuk’s proctoring and Prof. Damien Bolton’s support.
Niranjan Sathianathen retweeted
🚨Neurosafe RCT(n=407) at gamechanger sess by Greg Shaw #EAU25. In men with good baseline erections having RALP, 12 mth erectile function better with neurosafe technique vs SOC (IIEF 12.7vs9.7, p<0.001) & early continence better. Published @TheLancetOncol thelancet.com/journals/lanon…
Niranjan Sathianathen retweeted
Cancer Statistics 2025 are out! #prostatecancer incidence still on the rise, mortality basically flat. Get screened so you can get treatment _when needed_. #pcsm
acsjournals.onlinelibrary.wi…
Niranjan Sathianathen retweeted
Out now: Penile cancer care in the Netherlands: increased incidence, centralisation, and improved survival in @BJUIjournal by Manon Vreeburg and Oscar Brouwer #publicationoftheweek ⬇️ bit.ly/49FdYz4
Niranjan Sathianathen retweeted
1/4 Transperineal Versus Transrectal Magnetic Resonance Imaging–targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial - ScienceDirect. sciencedirect.com/science/ar…
Niranjan Sathianathen retweeted
Remembering Christchurch | a GU Cast Special. We put together this one hour video podcast to remember the devastating 2011 Christchurch Earthquake and explain why it matters to @USANZUrology @gu_onc Some amazing stories in there youtu.be/qenpYNofAQ8 – at Melbourne, Victoria
Niranjan Sathianathen retweeted
STOPCAP meta-analysis:
Docetaxel addition to ADT
➡️ limited OS/PFS benefit in low-volume metachronous mCSPC
➡️ best suited for high volume/potentially bulky/T4 primary tumors @ChrisSweens1 @BertrandTOMBAL @pgd81 @mattsydes @Prof_Nick_James sciencedirect.com/science/ar… #ProstateCancer
Niranjan Sathianathen retweeted
Cost-effectiveness of systemic treatment intensification in men with metastatic hormone-sensitive #ProstateCancer. Presented by @NiranjanJS @USANZUrology. #AUA23 written coverage by @rksayyid @UofT > bit.ly/3n9JRNh @AmerUrological
Niranjan Sathianathen retweeted
Diagnostic Accuracy of PSMA PET/CT for Initial Staging of Intermediate to High-risk Prostate Cancer: Systematic Review and Meta-analysis
"PSMA-PET should be used as a first-line approach for the initial staging of PCa."
sciencedirect.com/science/ar…
@EUplatinum @declangmurphy
Niranjan Sathianathen retweeted
🎯After 21 yrs in Rotterdam PCa screening study: Invite 246, diagnose 14 to prevent 1 death. Invite 121, diagnose 7 to prevent 1 metastatic case. Overdiagnosis now strongly reduced (risk stratification, MRI etc). Let's bring this advantage to all men who may benefit! @uroweb
Niranjan Sathianathen retweeted
Thanks to @NeuroAhmad for this critical piece on limited global diversity of Cochrane Urology authorship @BJUIjournal; more work to do @VikramNarayan @GiuliaILane @NiranjanJS @DraganIlic99 @onuralp_ergun @EBMUrology @juan_francomd @drimranomar bjui-journals.onlinelibrary.…
Niranjan Sathianathen retweeted
@JonathanSOBrien & @declangmurphy deliver one of highest quality videos of #EAU23 with slick, professional production values. This is how all videos should be put together! If only rest of our community had skills of this group.
Key message: RP is safe/feasible after #Lutectomy
Cutting edge presentation on the use of ICG during robotic ILND @JonathanSOBrien @lawrentschuk @gu_onc. Super slick AV @declangmurphy #EAU23 – at Milan, Lombardy
Great slide on factors to predict surgical outcome for LUTS +/- need for UDS before surgery @MarcusDrakeUrol #EAU23
